6 - What's Hot in ID + HIV

Wednesday, October 16, 2024

1:30 PM – 3:15 PM US PT

Location: Ballroom (West Hall B)

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.75 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.75 hours of MOC Credit
CNE Credits: Maximum of 1.75 hours of ANCC Credit
ACPE Credits: ACPE 1.75 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 2 of PACE contact hours
CE Broker: Maximum of 2 CE broker credit hours

Moderator(s)

Emily Erbelding, MD (she/her/hers)

Director, Division of Microbiology and Infectious Disease NIAID
National Institutes of Health
Rockville, MD, United States
Colleen Kelley, MD, MPH (she/her/hers)

Associate Professor of Medicine
Emory University
Decatur, GA, United States

Faculty(s)

Peter Hunt, MD (he/him/his)

Professor
University of California San Francisco
San Francisco, CA, United States
Allison Agwu, MD, MSc (she/her/hers)

Professor
Johns Hopkins University
Baltimore, MD, United States
David Relman, MD (he/him/his)

Thomas C. and Joan M. Professor
Stanford University
Stanford, CA, United States
Patty Wright, MD (she/her/hers)

Professor, Infectious Diseases
Medicine
Vanderbilt University Medical Center
Nashville, TN, United States

Disclosure(s):

Emily Erbelding, MD: No financial relationships to disclose

Colleen F. Kelley, MD, MPH: Gilead Sciences: Grant/Research Support (Ongoing); Humanigen, Inc: Grant/Research Support (Terminated); Moderna, Inc.: Grant/Research Support (Terminated); Novavax, Inc.: Grant/Research Support (Terminated); ViiV Healtcare: Grant/Research Support (Ongoing)

Peter W. Hunt, MD: Gilead Biosciences: Grant/Research Support (Ongoing), Honoraria (Ongoing); Merck Sharp & Dohme Corporation: Advisor/Consultant (Terminated, August 31, 2023), donated drug for NIH-sponsored clinical trial (Terminated, August 31, 2023); Viiv Healthcare: Advisor/Consultant (Terminated, March 30, 2023), Honoraria (Terminated, March 30, 2023)

Allison Agwu, MD, MSc: AbbVie, Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare: Advisor/Consultant (Terminated, December 20, 2023); Gilead Biosciences: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Terminated, December 31, 2022), Grant/Research Support (Terminated, December 31, 2022)

David A. Relman, MD: Blue Willow Biologics: Stocks/Bonds (Private Company) (Ongoing); Cantata Bio: Advisor/Consultant (Ongoing), Stocks/Bonds (Private Company) (Ongoing); Inflammatix Inc.: Host Response Diagnostic (Ongoing); Karius: Stocks/Bonds (Private Company) (Ongoing); ProdermIQ: Stocks/Bonds (Private Company) (Ongoing); Second Genome: Stocks/Bonds (Private Company) (Ongoing); Visby Medical: Advisor/Consultant (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe new developments in the field of clinical and epidemiological sciences in hiv;
explain new research findings in the field of basic hiv research.

Presentations:

1:30 PM – 1:55 PM US PT

What's Hot in HIV Basic Sciences
Speaker: Peter W. Hunt, MD (he/him/his) – University of California San Francisco
1:55 PM – 2:20 PM US PT

What's Hot in HIV: Clinical Sciences
Speaker: Allison Agwu, MD, MSc (she/her/hers) – Johns Hopkins University
2:20 PM – 2:45 PM US PT

What's Hot in ID Basic Sciences
Speaker: David A. Relman, MD (he/him/his) – Stanford University
2:45 PM – 3:15 PM US PT

What's Hot in ID Clinical Sciences
Speaker: Patty W. Wright, MD (she/her/hers) – Vanderbilt University Medical Center